CompletedNCT00566020
Official study titleStudy SCA106052, a Clinical Evaluation of BW430C (Lamotrigine) in Bipolar I Disorder- Long-term Extension Study (Extension of Study SCA104779 (NCT00550407))
This study has finished and is no longer accepting participants.
Multiple locations, including AichiBipolarityMedication studyAges 20+
- Countries
- Japan
- Sponsor
- GlaxoSmithKline
CompletedNCT00195845
What is this study about?This study assessed thinking abilities.
This study has finished and is no longer accepting participants.
In CambridgeBipolarityMedication studyAges 18–60
- Countries
- United States
- Sponsor
- Cambridge Health Alliance
WithdrawnNCT00512616
Official study titleAn Investigation of the Efficacy of the Glutamate Transporter GLT 1 in the Treatment of Bipolar Depression
This study was withdrawn before enrollment.
In BethesdaBipolarityMedication studyAges 18–65
- Countries
- United States
- Sponsor
- National Institute of Mental Health (NIMH) (Government agency)
CompletedNCT00606229
What is this study about?This study evaluated the safety and effectiveness of Aripiprazole for people with bipolarity.
This study has finished and is no longer accepting participants.
Multiple locations, including Chugoku RegionBipolarityMedication studyAges 18–65
- Countries
- Japan
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. (Pharmaceutical company)
CompletedNCT00606320
What is this study about?This study evaluated the safety and effectiveness of Aripiprazole for people with bipolarity.
This study has finished and is no longer accepting participants.
Multiple locations, including Hong KongBipolarityMedication studyAges 18–65
- Countries
- China, Japan, South Korea, + 1 other
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. (Pharmaceutical company)
CompletedNCT00606177
What is this study about?Researchers compared Aripiprazole and placebo to find out how the approaches affected manic symptoms in people with bipolarity.
This study has finished and is no longer accepting participants.
Multiple locations, including Hong KongBipolarityMedication studyAges 18–65
- Countries
- China, Japan, South Korea, + 1 other
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. (Pharmaceutical company)
CompletedNCT00606281
What is this study about?Researchers compared Aripiprazole and placebo to find out how the approaches affected manic symptoms in people with bipolarity.
This study has finished and is no longer accepting participants.
Multiple locations, including Hong KongBipolarityMedication studyAges 18–65
- Countries
- China, Japan, South Korea, + 1 other
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. (Pharmaceutical company)
TerminatedNCT02446509
Official study titleA Psychoeducation Intervention for Caregivers of Patients With Bipolar Disorder: A Feasibility Study
This study ended early.
In HoustonBipolarityBehavioural studyAges 18+
- Countries
- United States
- Sponsor
- The University of Texas Health Science Center, Houston
CompletedNCT04020289
Official study titleA Randomized Controlled Trial of a Psychoeducational Program"BalancingMySwing" for Patients With Bipolar Disorder
This study has finished and is no longer accepting participants.
Location not clearly listedBipolarityBehavioural studyAges 20–65
- Countries
- Sponsor
- National Cheng Kung University
CompletedNCT03017781
Official study titleAn Observational Longitudinal Study in Offspring of Parents With Bipolar Disorder to Evaluate the Relationship of Impairment in Psychosocial Functioning With the Manifestation of Mood Symptoms Over 24 Months
This study has finished and is no longer accepting participants.
Multiple locations, including Culver CityBipolarityObservational studyAges 15–25
- Countries
- United States
- Sponsor
- Janssen Research & Development, LLC
CompletedNCT00490971
What is this study about?Researchers compared Paliperidone ER, placebo and Olanzapine to find out how the approaches affected how long people remain free of a new mood episode in people with bipolarity type I.
This study has finished and is no longer accepting participants.
Multiple locations, including ScottsdaleBipolarityMedication studyAges 18–65
- Countries
- United States, France, Bulgaria, + 13 others
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedNCT00309699
What is this study about?Researchers compared Paliperidone ER, placebo and Quetiapine to find out how the approaches affected manic symptoms in people with bipolarity.
This study has finished and is no longer accepting participants.
Multiple locations, including CerritosBipolarityMedication studyAges 18–65
- Countries
- United States, Greece, Lithuania, + 5 others
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.